基本信息
views: 464
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Scientific progress is generating myriad opportunities for ground-breaking medicines and therapies, and it is my belief that industry has to pioneer new approaches to drug discovery and development to bring these therapies to patients. This ambition to challenge the status quo sits at the very heart of my approach to both science and leadership.
Whether it’s engineering new models of collaboration with academia (e.g. GSK’s Immunology Network), simplifying processes and ways of working (to reduce PII cycle times by c.50% at GSK), or sponsoring disruptive technologies and business models (e.g. in the Flagship Pioneering biotech Kintai Therapeutics that invented Precision Enteric Medicines), I aim to bring creative, energising and empowering leadership to all that I do.
In my own career, I’ve been at my best when I’ve had the freedom to think and explore, be stimulated by others’ points of view and able to challenge received wisdom. These are the principles that guide my approach to leadership and that help me to unite teams around ideas and drive outstanding performance. I also believe these principles build a collaborative and inspiring culture that is able to realize the many opportunities ahead of us.
Whether it’s engineering new models of collaboration with academia (e.g. GSK’s Immunology Network), simplifying processes and ways of working (to reduce PII cycle times by c.50% at GSK), or sponsoring disruptive technologies and business models (e.g. in the Flagship Pioneering biotech Kintai Therapeutics that invented Precision Enteric Medicines), I aim to bring creative, energising and empowering leadership to all that I do.
In my own career, I’ve been at my best when I’ve had the freedom to think and explore, be stimulated by others’ points of view and able to challenge received wisdom. These are the principles that guide my approach to leadership and that help me to unite teams around ideas and drive outstanding performance. I also believe these principles build a collaborative and inspiring culture that is able to realize the many opportunities ahead of us.
Research Interests
Papers共 1190 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
CANCER RESEARCHno. 7 (2024)
Francesca Barone,Alexander Ling,Isaac H. Solomon,Ana Montalvo Landivar,Hiroshi Nakashima,Andrea Manzanera, Maria Lucia Silva Polanco,Andres Santos,Nafisa Masud,Patrick Wen, Keith Leigon,David Reardon,
MOLECULAR THERAPYno. 5 (2023): 2-3
Cited0Views0Bibtex
0
0
Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)
Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)
Francesca Barone,Paul P Tak,Mark Bloomston, Elizabeth Webber, Jessica Dwyer,W Garrett Nichols, David Huitzil, Vanessa Rosas-Camargo, Marcos Ramirez-Marquez, Alejandra Murillo-Cordova, Randy Swan
Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)
Charu Aggarwal,Daniel Sterman,Fabien Maldonado,Christine M. Bestvina,Janani S. Reisenauer,Howard Li,Sonam Puri, Omar Ibrahim, Randy Swan, Audra Caine,Lenika Lopez,Andrea G. Manzanera,
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): TPS9162-TPS9162
FRONTIERS IN MEDICINE (2023): 1140352-1140352
Load More
Author Statistics
#Papers: 1182
#Citation: 71868
H-Index: 124
G-Index: 245
Sociability: 9
Diversity: 1
Activity: 1
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn